GlycoMimetics (GMI), based in Gaithersburg, MD, was founded via the acquisition of assets and expertise from GlycoTech, who developed technology to identify and assay carbohydrate mimics initially through a collaboration with Ciba-Geigy, now Novartis (NYSE: NVS), and then independently. These assay capabilities were out-licensed to Wyeth, now Pfizer (NYSE: PFE). Today, GMI holds or has [...]